DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Ocular Pain - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Ocular Pain Overview
- Therapeutics Development
- Pipeline Products for Ocular Pain - Overview
- Pipeline Products for Ocular Pain - Comparative Analysis
- Ocular Pain - Therapeutics under Development by Companies
- Ocular Pain - Therapeutics under Investigation by Universities/Institutes
- Ocular Pain Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Ocular Pain - Products under Development by Companies
- Ocular Pain - Products under Investigation by Universities/Institutes
- Ocular Pain - Companies Involved in Therapeutics Development
- InSite Vision Incorporated
- Kala Pharmaceuticals, Inc.
- Ocular Therapeutix, Inc.
- Reata Pharmaceuticals, Inc.
- Sylentis S.A.U.
- Valeant Pharmaceuticals International, Inc.
For more information visit http://www.researchandmarkets.com/research/7sn942/ocular_pain
